狄欧戈他明通过向转化生长因子βII型受体来改善肝纤维化
Ke-Xin Zheng1, Shou-Li Yuan2,3, Meng Dong2
1Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
World journal of gastroenterology
|June 22, 2023
概括
乙醇胺 (DHE) 通过向TGFβR2并抑制TGFβ信号通路来缓解肝纤维化. 这种重新设计的药物通过减少纤维化标志物和改善肝功能,显示出治疗肝纤维化的巨大潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 药物重用 药物重用
背景情况:
- 转化生长因子β (TGFβ) 信号通路是肝纤维化发展的组成部分.
- 激活TGFβII型受体 (TGFβR2) 启动下游信号级联,促进纤维化.
研究的目的:
- 确定食品和药物管理局批准的抑制TGFβR2和TGFβR1/TGFβR2复合体形成的药物.
- 评估这些药物在改善肝纤维化的潜力.
主要方法:
- 虚拟分子对接选了FDA批准的药物,以检测TGFβR2结合亲和力.
- 细胞计数工具-8测定了经过验证的药物毒性,并确定了最佳度.
- 突变酶分析阐明了分子作用机制.
- 一个小鼠模型在体内评估了抗纤维菌疗效.
主要成果:
- 鉴定了六种候选药物,其中二能草胺 (DHE) 显示出显著的疗效.
- 在TGFβ诱导的LX-2细胞模型中,DHE降低了纤维化基因表达 (原,p-SMAD3,α-SMA).
- 在特定的残留物 (Leu27, Phe30, Thr51, Ser52, Ile53, Glu55) 上,DHE直接与TGFβR2结合.
- 在体内,DHE改善了肝纤维化,减少了门静脉异常,减少了炎症标志物和细胞外基质沉积.
结论:
- 迪欧戈他明通过与TGFβR2结合来缓解肝纤维化,有效抑制TGFβ信号通路.
- 作为用于治疗肝纤维化的重用药物,DHE显示出相当大的潜力.
相关概念视频
01:24Liver Regeneration
3.3K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
204
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
204
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15